AyuVis Research is selected for Virtual BLUE KNIGHT? and Johnson & Johnson Innovation –?JLABS Residency. Read it here: https://lnkd.in/gMd5CKu2 AyuVis’ first target indication is the prevention of bronchopulmonary dysplasia (BPD), a chronic lung disease in preterm babies where there are no available FDA-approved therapies. Follow-on indications with high unmet medical need include the treatment of acute respiratory distress syndrome (ARDS) and ventilator-associated pneumonia (VAP). AyuVis is a multi-asset, multi-indication biotech company.
AyuVis Research, Inc.
生物技术研究
Fort Worth，TEXAS 841 位关注者
Innovation in Immunotherapy to Treat Inflammation and Infection
关于我们
AyuVis is a start-up biopharmaceutical company focusing on developing New Molecular Entities (NME) as immune modulating, anti-microbial, and anti-inflammatory drugs. Our pipeline of drug candidates is based on a new platform technology that modulates macrophages in the innate immune system to restore balance while fighting both infection and inflammation. Stimulating these macrophages produces a rapid therapeutic response throughout the body as we have seen in our strong preclinical data. This is unlike any existing immunotherapies today - immunotherapies which in total have annual sales of $70B. Because the antimicrobial action of our compounds is through the activation of phagocytosis, the development of multidrug resistance is not anticipated. Our goal is to save and improve lives, reduce hospital costs, & provide an effective treatment to diseases like BPD, VAP, and ARDS with no adverse side effects that are seen with the current alternatives. Our lead candidate is Orphan Drug and Rare Pediatric Disease Designated by the US FDA for the prevention of bronchopulmonary dysplasia (BPD) in at-risk preterm infants. BPD is a rare pediatric lung disease in preterm babies caused by inflammation from supplemental oxygen required for survival in the NICU and is the second leading cause of death in preterm babies. An average of 112 preterm babies die per month in the US due to the lack of an effective therapy and survivors require ongoing care. AyuVis has 2 patents approved by the USPTO and more countries which include composition of matter of our compounds, methods of use, formulations, and more.
- 网站
-
https://www.ayuvis.com
AyuVis Research, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Fort Worth，TEXAS
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Medicinal Chemistry、Small Molecule Drug Discovery、Dry and Wet AMD - Inflammation, Angiogenesis、Immunomodulation - Septic shock、Immunotherapy、Bronchopulmonary Dysplasia、Ventilator-associated Pneumonia、ARDS和Antimicrobial
地点
-
主要
获取路线
3500 Camp Bowie Blvd
EAD-116J
US，TEXAS，Fort Worth，76107
AyuVis Research, Inc.员工
-
Ranjan Misra
CEO/President/COO/Board Member/Advisor - President, COO Hitec Power Protection, Inc./Manufacturing/UPS/IT Services
-
Suchismita Acharya, PhD
CEO, AyuVis Research Inc
-
Dr. Sumita Behera
Senior Research Scientist
-
Eesha Acharya
Aspiring Baylor University undergrad | Research scholar | Global health advocate
动态
-
AyuVis is eager to announce that the investigational new drug, AVR-48, has been granted Fast Track Designation by the US FDA for the prevention of bronchopulmonary dysplasia (BPD) in preterm babies. Founder and CEO Suchismita Acharya, PhD says, "We are very excited about the progress of our project into clinical trials. Getting all three designations — Orphan Drug, Rare Pediatric Disease, and Fast Track Designations — one after another is a great testament to our team's diligent effort to expedite the development of AVR-48 and bring preventive therapy to the neonates most in need.” The company is transitioning to clinical stage and anticipating to begin a Phase 1 clinical trial later this year. Learn more about the novel, small molecule immunotherapy AVR-48 and why it is the potential answer to prevent BPD in the press release below! #FastTrack #Immunotherapies #BiotechInnovation https://lnkd.in/eAFuXCFS
-
Congratulations Charles
Commencement 2024. Congratulations to Dr. Charles Amankwa for successfully completing his PhD thesis in Biomedical Science under my guidance. It was a pleasure working with, mentoring, and co-authoring several publications with Charles. He is a very bright scientist. Wishing you all the best for your future career.
-
-
Don't miss the oral presentation by David Riley, MD, MBA at the American Thoracic Society International Conference next week! On Tuesday, May 21 at 10:51 am PDT, Dr. Riley will share the results of AyuVis' large animal efficacy study for the prevention of BPD. The objective of the study was to determine long-term outcomes for survival, growth, respiratory mechanics, and neurobehavior in former preterm lambs treated with AyuVis' lead compound, AVR-48, measured at ages comparable to human infants at 12-18 months. These are results you won't want to miss! See the presentation details here: https://lnkd.in/g5YK3NMC #ATS2024 #biotechinnovation #immunotherapy
-
-
Catch Suchismita Acharya, PhD at the Respiratory Innovation Summit at the American Thoracic Society International Conference in San Diego this weekend! Today and tomorrow she will be presenting a poster on AyuVis' novel immunotherapies to Prevent and Treat Rare Pediatric and Adult Lung Injuries and Infections. Find her at poster 120 to learn more. See the agenda here: https://lnkd.in/dRujG49e #ATS2024 #RIS2024
-
-
It was a great afternoon yesterday attending the BIO town hall meeting discussing topics that affect start-ups and the life science industry, including regulatory, manufacturing, and Capital formation. Meeting in person with the BIO CEO John Crowley was an absolute pleasure. #BIO #lifescience #startups #townhallmeeting #AyuVis Research
-
-
Celebrating Mothers and Innovation: AyuVis is committed to bringing therapy for Bronchopulmonary Dysplasia and Empowering Mother and infant's Health. On this Mother's Day, AyuVis honors all the incredible strength and unconditional love that mothers bring into our lives. We recognize the profound importance of mother's well-being for families and communities. At AyuVis, we work towards a dual mission: finding a cure for bronchopulmonary dysplasia (BPD) and promoting women's health. Bronchopulmonary dysplasia is a chronic lung disease that affects thousands of families each year. Our team at AyuVis is harnessing cutting-edge research to develop novel therapies that offer real hope for these vulnerable newborns. We believe in collaborating with researchers, healthcare professionals, and affected families to accelerate progress towards a cure. We understand that BPD doesn't just impact the health of newborns - it profoundly affects their mothers and caregivers. Long hospital stays, frequent medical visits, and the emotional toll of uncertainty can take a significant burden on mothers. We are committed to not only finding a cure but also supporting mothers with educational resources, support networks, and practical assistance. Our goal is to make sure no mother feels alone in her journey through her baby's health challenges. Happy Mother's Day to all the incredible mothers and caregivers out there. Together, we can make this world a healthier, brighter place. #MothersDay2021 #AyuVis #BPD #Healthcare #Innovation
-
-
Meet with AyuVis at this year's BIO International Convention in San Diego, CA. Suchismita Acharya, PhD and Mariam Morris, are looking forward to connect and collaborate June 3-6, 2024. #BIO2024 https://lnkd.in/dKrXuHVa
-
-
Come find us in #Toronto this week! The AyuVis team is headed to the Pediatric Academic Societies Meeting to present two posters on our novel, small molecule immunotherapies' unique mechanism of action to address inflammation. We look forward to engaging with fellow innovators, physicians, and pharmaceutical companies with a vested interest in solving critical unmet needs in pediatrics. Details on Suchismita Acharya, PhD poster: https://lnkd.in/gMdMUbGd Details on Adam S. Dayoub, PhD poster: https://lnkd.in/gqS3p6Tz #PAS2024 #pedatrics #inflammation #biotech
-